Polypharmacy in Patients with Chronic Kidney Disease

Ilse J Oosting; Julia M T Colombijn; Lotte Kaasenbrood; Sophie Liabeuf; Solène M Laville; Lotty Hooft; Michiel L Bots; Marianne C Verhaar; Robin W M Vernooij

doi:10.34067/KID.0000000000000447

Polypharmacy in Patients with Chronic Kidney Disease

Kidney360. 2024 Apr 25. doi: 10.34067/KID.0000000000000447. Online ahead of print.

Authors

Ilse J Oosting^{1

2}, Julia M T Colombijn^{1

2}, Lotte Kaasenbrood¹, Sophie Liabeuf^{3

4}, Solène M Laville^{3

4}, Lotty Hooft^{2

5}, Michiel L Bots², Marianne C Verhaar¹, Robin W M Vernooij^{1

2}

Affiliations

¹ Department of Nephrology and Hypertension, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
² Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
³ MP3CV Laboratory, EA7517, Jules Verne University of Picardie, F-80000 Amiens, France.
⁴ Pharmacoepidemiology Unit, Department of Clinical Pharmacology, Amiens University Medical Center, F-80000 Amiens, France.
⁵ Cochrane Netherlands, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.

PMID: 38661553
DOI: 10.34067/KID.0000000000000447

Abstract

Background: Despite the high prevalence of polypharmacy in patients with chronic kidney disease (CKD), the extent of polypharmacy across patients with (different stages of) CKD, as well as the association with clinical outcomes remains unknown. This systematic review aimed to evaluate the prevalence of polypharmacy in (different subgroups of) patients with CKD and assess the association between polypharmacy and patient-important outcomes.

Methods: Medline, Embase, and the Cochrane Library were searched from inception until July 2022. Studies that reported the prevalence of polypharmacy, medication use, or pill burden in patients with CKD (including patients receiving dialysis and kidney transplant recipients) and their association with patient-important outcomes (i.e. mortality, kidney failure, quality of life, and medication non-adherence) were included. Two reviewers independently screened title and abstract and full texts, extracted data, and assessed risk of bias. Data were pooled in a random-effects single-arm meta-analysis.

Results: In total, 127 studies were included (CKD 3-5 n=39, dialysis: n=38, kidney transplant n=13, different CKD stages n=37). The pooled prevalence of polypharmacy, based on 63 studies with 484,915 patients, across all patients with CKD was 82% (95% confidence interval [CI]: 76-86%) and the pooled mean number of prescribed medications 9.7 (95%CI: 8.4-11.0). The prevalence of polypharmacy was higher in patients who received dialysis or a kidney transplant compared to patients with CKD 3-5, but did not differ between studies with regards to region, or patients' mean age or sex. In patients with CKD, polypharmacy was associated with a higher risk of all-cause mortality, kidney failure, faster eGFR decline, lower quality of life (QoL), and higher medication non-adherence, adverse drug reactions, and potentially inappropriate medications.

Conclusions: The prevalence of polypharmacy in patients with CKD was over 80%, and highest in patients with a kidney transplant and those receiving dialysis. No causes of heterogeneity were identified, indicating that polypharmacy is an issue for all patients with CKD. Polypharmacy is associated with worse clinical outcomes, lower QoL, and medication-related problems in patients with CKD.